HOME > LATEST
LATEST
-
REGULATORY LDP Drug Innovation Project Team Eyes Inclusion of MCMs in Honebuto
April 15, 2025
-
BUSINESS Welcia, Tsuruha to Merge in December 2025 to Create Top Drugstore Group
April 15, 2025
-
BUSINESS AstraZeneca Eyes 40 Approvals by 2030 in Japan, Driven by New Modalities
April 15, 2025
-
BUSINESS Servier Poised to Double Japan Workforce over Next 3 Years: CEO, Local Chief
April 14, 2025
-
REGULATORY Chugai’s DMD Gene Therapy Up for Japan Panel Review on April 18
April 14, 2025
-
REGULATORY MHLW Panel to Review Moderna’s RSV Jab, GSK’s ADC, and More on April 21
April 14, 2025
-
REGULATORY Japan Govt Ends Subsidies for COVID Vaccinations from FY2025
April 14, 2025
-
REGULATORY Scrap Coverage for OTC-Like Drugs with Same APIs and Dose as OTC Meds: Nippon Ishin
April 14, 2025
-
BUSINESS RaQualia Ends Tamibarotene License Pact with Syros
April 14, 2025
-
ORGANIZATION JGA to Release Interim Report on Industry Revamp in June: President
April 14, 2025
-
BUSINESS Japan Biotechs to Be Hit Hard by TSE Growth Market Reform, 26 Firms Fail to Reach Proposed Threshold
April 11, 2025
-
REGULATORY Generic Dispensing Rates Spike on New LLP Coverage Rule: Survey
April 11, 2025
-
REGULATORY 250 LDP Lawmakers Sign Petition for Revisiting Budget Cap, Off-Year Cuts
April 11, 2025
-
REGULATORY MHLW on Alert for Potential Tariffs on Osteomalacia, Schizophrenia Meds
April 11, 2025
-
REGULATORY Nippon Ishin Co-Leader Shows Understanding of Off-Year Price Revisions
April 11, 2025
-
REGULATORY Clinical Trial Matching Websites Do Not Violate Ad Regulations in PMD Act: MHLW
April 10, 2025
-
REGULATORY MHLW Sets Up Task Force to Brace for US Tariffs
April 10, 2025
-
REGULATORY Repeal of Off-Year Revision Means No Price Raise for Unprofitable Drugs: Minister
April 10, 2025
-
REGULATORY Bill to Nix Off-Year Scheme Politicized, Could Clear Lower House with Ishin Support
April 10, 2025
-
BUSINESS Kaken Bags Japan Commercial Rights to KalVista’s HAE Drug
April 10, 2025
ページ
I recently attended a fantastic conference hosted by Prospection Japan, and one speaker, Dr. Joe Ledsam, really blew me away with his insights. He shared some truly fascinating developments about how AI is set to revolutionize healthcare, from how doctors…
For the first time in many years, Japan appeared to have pivoted to a pro-innovation path with the FY2024 drug pricing reform. All eyes were apparently on this course change as seen in this year’s most-read story list, though the…
The Ministry of Health, Labor and Welfare (MHLW) posted the final report compiled by its pharmaceutical regulation panel on its website on April 24, providing cases of drugs that could be exempted from all-case post marketing surveillance (PMS).The MHLW plans…